Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;19(1):47-56.
doi: 10.1111/ddg.14308. Epub 2020 Dec 30.

Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis

Shanshan Xu  1   2 , Xing Gao  1   2 , Jixiang Deng  1   2 , Jiajia Yang  1   2 , Faming Pan  1   2
Affiliations

Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis

Shanshan Xu et al. J Dtsch Dermatol Ges. 2021 Jan.

Abstract

Objective: To compare the efficacy and safety of biologics for patients with moderate to severe plaque psoriasis.

Methods: We systematically reviewed 60 randomized controlled trials (34,020 participants), which compared 14 biological drugs for treatment of moderate to severe plaque psoriasis. The main assessment criteria were ≥ 90 % reductions in Psoriasis Area and Severity Index (PASI 90) and the number of patients who reported treatment-emergent adverse events (AEs). Secondary criteria were ≥ 75 % reductions in Psoriasis Area and Severity Index (PASI 75), Physician's Global Assessment 0/1 (PGA 0/1) and infections.

Results: This network meta-analysis showed that biologics were significantly more effective than placebo. Ixekizumab, risankizumab, and bimekizumab were among the most effective treatments, and tildrakizumab, guselkumab and risankizumab were better than the other drugs with respect to safety. Risankizumab and guselkumab performed relatively stable with respect to both efficacy and safety. At the class level, blockers of interleukin (IL)-17A showed favorable efficacy while inhibitors of the p19 subunit of IL-23 were best tolerated of all efficient biologics.

Conclusions: Ixekizumab was the most effective biologic in PASI 90, while IL-23p19 inhibitors, risankizumab and guselkumab performed relatively stable with respect to efficacy and safety.

PubMed Disclaimer

References

    1. Goff KL, Karimkhani C, Boyers LN et al. The global burden of psoriatic skin disease. Br J Dermatol 2015; 172(6): 1665-8.
    1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31(2): 205-12.
    1. Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386(9997): 983-94.
    1. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12: Cd011535.
    1. Greb JE, Goldminz AM, Elder JT et al. Psoriasis. Nat Rev Dis Primers 2016; 2: 16082.

Publication types

Substances

LinkOut - more resources